These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 22974537)

  • 1. Losing sight of the wood for the trees: some issues in describing and valuing health, and another possible approach.
    Dolan P; Lee H; Peasgood T
    Pharmacoeconomics; 2012 Nov; 30(11):1035-49. PubMed ID: 22974537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Valuing SF-6D Health States Using a Discrete Choice Experiment.
    Norman R; Viney R; Brazier J; Burgess L; Cronin P; King M; Ratcliffe J; Street D
    Med Decis Making; 2014 Aug; 34(6):773-86. PubMed ID: 24025661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic review of SF-6D health state valuation studies.
    Wang L; Poder TG
    J Med Econ; 2023; 26(1):584-593. PubMed ID: 36973235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimating the SF-6D value set for a population-based sample of Brazilians.
    Cruz LN; Camey SA; Hoffmann JF; Rowen D; Brazier JE; Fleck MP; Polanczyk CA
    Value Health; 2011; 14(5 Suppl 1):S108-14. PubMed ID: 21839880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An investigation into the empirical validity of the EQ-5D and SF-6D based on hypothetical preferences in a general population.
    Petrou S; Hockley C
    Health Econ; 2005 Nov; 14(11):1169-89. PubMed ID: 15942981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valuing benefits to inform a clinical trial in pharmacy : do differences in utility measures at baseline affect the effectiveness of the intervention?
    Tinelli M; Ryan M; Bond C; Scott A
    Pharmacoeconomics; 2013 Feb; 31(2):163-71. PubMed ID: 23329427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What Difference Does It Make? A Comparison of Health State Preferences Elicited From the General Population and From People With Multiple Sclerosis.
    Goodwin E; Green C; Hawton A
    Value Health; 2020 Feb; 23(2):242-250. PubMed ID: 32113630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measuring and valuing mental health for use in economic evaluation.
    Brazier J
    J Health Serv Res Policy; 2008 Oct; 13 Suppl 3():70-5. PubMed ID: 18806195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The estimation of a preference-based measure of health from the SF-12.
    Brazier JE; Roberts J
    Med Care; 2004 Sep; 42(9):851-9. PubMed ID: 15319610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Portuguese value set for the SF-6D.
    Ferreira LN; Ferreira PL; Pereira LN; Brazier J; Rowen D
    Value Health; 2010 Aug; 13(5):624-30. PubMed ID: 20230545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The estimation of a preference-based measure of health from the SF-36.
    Brazier J; Roberts J; Deverill M
    J Health Econ; 2002 Mar; 21(2):271-92. PubMed ID: 11939242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sf-6d population norms.
    van den Berg B
    Health Econ; 2012 Dec; 21(12):1508-12. PubMed ID: 22250070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of contemporaneous EQ-5D and SF-6D responses using scoring algorithms derived from similar valuation exercises.
    Whitehurst DG; Norman R; Brazier JE; Viney R
    Value Health; 2014 Jul; 17(5):570-7. PubMed ID: 25128050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient and public preferences for health states associated with AMD.
    Butt T; Dunbar HM; Morris S; Orr S; Rubin GS
    Optom Vis Sci; 2013 Aug; 90(8):855-60. PubMed ID: 23811607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D.
    Walters SJ; Brazier JE
    Health Qual Life Outcomes; 2003 Apr; 1():4. PubMed ID: 12737635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensively Measuring Health-Related Subjective Well-Being: Dimensionality Analysis for Improved Outcome Assessment in Health Economics.
    de Vries M; Emons WH; Plantinga A; Pietersma S; van den Hout WB; Stiggelbout AM; van den Akker-van Marle ME
    Value Health; 2016; 19(2):167-75. PubMed ID: 27021750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do Portuguese and UK health state values differ across valuation methods?
    Ferreira LN; Ferreira PL; Rowen D; Brazier JE
    Qual Life Res; 2011 May; 20(4):609-19. PubMed ID: 21061071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges in health state valuation in paediatric economic evaluation: are QALYs contraindicated?
    Ungar WJ
    Pharmacoeconomics; 2011 Aug; 29(8):641-52. PubMed ID: 21604821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Comparison of UK and Brazilian SF-6D Preference Weights When Applied to a Brazilian Urban Population.
    Ferraz MB; Nardi EP; Campolina AG
    Value Health Reg Issues; 2019 Dec; 20():21-27. PubMed ID: 30634088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.